Gosset
Book a demo

ESMO Immuno-Oncology Congress 2025: key results and trends

What the 603 abstracts at ESMO Immuno-Oncology Congress 2025 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.

abstracts
603
drug-linked abstracts
304
companies
90
from Phase 3 studies
43

Drug-linked abstracts by phase

  • Phase 1 21
  • Phase 1/2 16
  • Phase 2 73
  • Phase 2/3 2
  • Phase 3 43
  • Phase 4 2

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Triple-negative breast cancer (TNBC)

    avelumab

    A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

    In a descriptive analysis, avelumab reduced the hazard of OS events: HR 0.66, 95% CI 0.45-0.97.

    Read the abstract (opens in a new tab)

  2. Phase 3Metastatic colon cancer (mCRC)Pfizer

    encorafenib

    First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study

    Median PFS by BICR was 14.0 vs 7.1 mo, and median OS was not estimable (NE) vs 13.7 mo for EC+mFOLFOX6 vs control.

    Read the abstract (opens in a new tab)

  3. Phase 3Hepatocellular carcinoma (HCC)AstraZeneca

    durvalumab + tremelimumab

    Pooled efficacy and safety with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the mainland China extension cohort, and Hong Kong (HK) and Taiwan (TW) subgroups from the global cohort in the phase III HIMALAYA study

    OS HRs (95% CI) were 0.60 (0.42–0.84) for STRIDE and 0.68 (0.49–0.96) for D vs S.

    Read the abstract (opens in a new tab)

  4. Phase 3Cervical cancer (mCC)

    tisotumab vedotin

    Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301

    Median (95% CI) OS was not reached (9.7 months–not estimable) with TV vs 10.7 months (6.0-not estimable) with chemotherapy (HR 0.55; 95% CI 0.27–1.15).

    Read the abstract (opens in a new tab)

  5. Phase 3Gastric adenocarcinoma

    retlirafusp alfa

    SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ≥1: A post-hoc analysis of a phase III study

    Median OS was 16.7 months (95% CI, 14.4-18.5) in the SHR-1701 group versus 10.3 months (95% CI, 9.3-12.1) in the placebo group (HR=0.56; 95% CI, 0.45-0.71).

    Read the abstract (opens in a new tab)

  6. Phase 3Non-small cell lung cancer (NSCLC)BeyondSpring

    plinabulin

    Plinabulin/docetaxel vs. docetaxel in 2L/3L EGFRwt NSCLC after platinum regimens (DUBLIN-3): Asian subgroup analysis

    At 24-months (Mo) follow-up after database lock (DB), the survival benefit persisted with mOS favoring DP (10.8 vs. 8.8 Mo, HR=0.80, p=0.0300), and more pronounced in non-squamous (NSQ) pts (11.4 vs. 8.4 Mo, HR=0.69, p=0.0064).

    Read the abstract (opens in a new tab)

  7. Phase 3Small cell lung cancer (SCLC)

    lurbinectedin

    Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC): IMforte Asia subgroup results

    At data cutoff (29 Jul 2024), IRF-PFS was improved with lurbi + atezo vs atezo (median, 6.3 vs 1.8 mo; unstratified HR, 0.48; 95% CI: 0.27, 0.87), as was OS (median, 16.5 vs 12.2 mo; unstratified HR, 0.81; 95% CI: 0.37, 1.75).

    Read the abstract (opens in a new tab)

  8. Phase 3Well-differentiated thyroid cancer (WDTC)Novartis

    dabrafenib + trametinib

    Safety profile of dabrafenib plus trametinib (D+T) in previously treated Chinese Mainland subgroup (CMS) population with radioactive iodine (RAI)–refractory BRAF V600E mutation–positive differentiated thyroid cancer (DTC)

    The incidence of grade ≥3 AEs was higher in the D+T (52.8%) than the PBO arm (21.7%).

    Read the abstract (opens in a new tab)

  9. Phase 2/3Pancreatic cancer (PDAC)HUTCHMED

    surufatinib

    Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II/III study

    With the median PFS follow-up duration of 8.15 months (m), S+C+AG demonstrated superior median PFS vs AG (7.20m vs 5.52m, stratified hazard ratio [HR] 0.499, log-rank P = 0.0407).

    Read the abstract (opens in a new tab)

  10. Phase 2Gastric adenocarcinoma

    adebrelimab

    Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma

    The ASO group achieved significantly higher pCR rates compared to PSO group (25.45% vs 1.82%, p<0.0001), with marked tumor downstaging (ypT0: 25.45% vs 1.82%; ypN0: 65.45% vs 21.82%, both p<0.0001).

    Read the abstract (opens in a new tab)

  11. Phase 2Metastatic colon cancer (mCRC)

    fruquintinib

    Fruquintinib combined with TAS-102 with or without SBRT as third- or later-line treatment in metastatic colorectal cancer : Preliminary results from a prospective phase II trial

    ORR was 36.4% (4/11) in FTS vs 12% (3/25) in FT,and mPFS was not reached in FTS vs 8.58 months (95% CI: 4.57–9.00) in FT.

    Read the abstract (opens in a new tab)

  12. Phase 1Non-small cell lung cancer (NSCLC)Boehringer Ingelheim

    zongertinib

    Zongertinib in HER2-mutant advanced NSCLC: Impact of therapy line on efficacy

    In patients who received 3L zongertinib, the confirmed ORR was 75.0% (46.8–91.1)

    Read the abstract (opens in a new tab)

Small molecules were the most frequent modality (50% of drug-linked abstracts). PDCD1 was the most frequent target (18%). Non-small cell lung cancer (NSCLC) was the most frequent disease (26%).

What the abstracts covered

Share of the 304 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Antibody-drug conjugates9%28 drug-linked abstracts
  • Bispecific antibodies5%14 drug-linked abstracts

Top targets

  1. PDCD15518%
  2. EGFR3110%
  3. CD274269%
  4. ERBB2269%
  5. TUBB165%
  6. MET145%
  7. VEGFR2145%
  8. VEGFR4145%
  9. VEGFR-1134%
  10. RET124%

Top modalities

  1. Small molecules15350%
  2. Monoclonal antibodies9331%
  3. Antibody-drug conjugates289%
  4. Bispecific antibodies145%
  5. Non-antibody therapeutic proteins72%
  6. Natural-product mixtures and botanicals62%
  7. Peptides52%
  8. Vaccines31%

Top diseases

  1. Non-small cell lung cancer (NSCLC)7826%
  2. Breast cancer3411%
  3. Gastric cancer (GC)186%
  4. Hepatocellular carcinoma (HCC)176%
  5. Head and neck squamous cell carcinoma (HNSCC)134%
  6. Gastric adenocarcinoma93%
  7. Gastroesophageal junction adenocarcinoma93%
  8. Prostate cancer (PCa)93%
  9. Colorectal cancer (CRC)83%
  10. Pancreatic cancer (PC)83%

Most active companies

  1. AstraZeneca2910%
  2. Bristol Myers Squibb186%
  3. Merck165%
  4. Genentech103%
  5. Pfizer103%
  6. HUTCHMED93%
  7. Jiangsu HengRui Medicine Co., Ltd.93%
  8. Eisai83%
  9. Henlius83%
  10. BeiGene72%

Explore every ESMO IO 2025 result in Gosset

All 304 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Get full accessExplore the results in Gosset

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call